Pharmaceutical company Sarepta (NASDAQ: SRPT) was up another 26% for November, adding to its mind-boggling gains totaling 550% for the year. Its Duchenne muscular dystrophy drug Eteplirsen has actually increased the distance patients with the disease can walk in clinical trials, rather than only slowing the disease's progression, and may represent a fundamental milestone in our treatment of the disease from now on. November's big price driver for the company was Piper Jaffray's upgrade of the company, pegging it for the near term at a target price range of $60 to $80 and saying the stock could reach as high as $160. Because this is a biotech stock with its hopes pinned solely on a single drug still in the testing phase, however, this is an investment that only those with a high tolerance for risk should pursue.
See more in the following video.
David Williamson has no positions in the stocks mentioned above. Follow him on Twitter, @MotleyDavid. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline and Vertex Pharmaceuticals. Motley Fool newsletter services recommend GlaxoSmithKline and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.